Rhizen Pharmaceuticals AG is a Swiss HQ biotech company that is dedicated to developing innovative, small molecule drugs for the treatment of cancer & inflammatory diseases. Its slogan, "Developing The Next Generation Medicines That Will Lead The Fight Against Cancer," reflects its commitment to creating impactful solutions. Rhizen has established itself as a leader in the PI3K space with the discovery of Umbralisib & Tenalisib - class leading PI3K isoform-specific inhibitors aimed at transforming the NHL & CLL space. Since its foundation in 2012, the company has built a deep pipeline of novel differentiated assets across various stages of development. As a player in the Biotechnology and Pharmaceutical industries, Rhizen Pharmaceuticals AG is poised for significant growth and impact in the fight against cancer and inflammatory diseases.
There is no investment information
No recent news or press coverage available for Rhizen Pharmaceuticals AG.